An amino acid for a healthy heart
- A natural nitric oxide precursor
- Protects the heart from high blood sugar levels
- Helps in cellular energy production
$41.19 — or subscribe and save 20%
Out of stock
Arginine is an amino acid with many important health benefits, but is best known for its key role in the production of nitric oxide, a potent factor in relaxing blood vessels and promoting blood flow. By increasing nitric oxide levels, Arginine has the ability to prevent plaque and blood clot formation and reduce the stickiness of platelets. Clinical studies have found high doses of arginine beneficial for many cardiovascular conditions including high blood pressure, peripheral vascular disease and angina.
In addition to its effects on blood vessels, arginine enhances the release of human growth hormone (hGH), enhances insulin sensitivity, supports liver detoxification, and has been shown to support interstitial cystitis, sperm formation, and treatment of brain injuries.
AOR offers a high quality arginine supplement to enhance cardiovascular and overall health.
Arginine is a conditionally essential amino acid and the main precursor in the body in the synthesis of nitric oxide (NO), now accepted to be the “endothelium-derived relaxation factor (EDRF).” The endothelium makes up the lining of the heart and blood vessels.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal by product.
Take three capsules one to three times daily on an empty stomach, or as directed by a qualified health care practitioner.
Do not use if you have had a myocardial infarction (heart attack), if you have asthma or if you are pregnant or breastfeeding. Consult a health care practitioner prior to use if you are taking cardiovascular medications, potassium increasing drugs or sildenafil.
- Supports exercise capacity
- Nitric oxide production
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Non-medicinal Ingredients: sodium stearyl fumarate. Capsule: hypromellose.
This publication is a systematic review of meta-analysis aimed at evaluating the effect of arginine on nitric oxide production, leading to an effect on blood pressure and immune regulation. This review covered meta-analysis that had been published from 1985 through to 2015; 7 meta-analysis were included in this review, each showing a significant positive benefit of arginine supplementation in reducing both systolic and diastolic blood pressure in hypertensive adults and pregnant women with gestational hypertension. Additionally, arginine supplementation corresponded with a 40% reduction in the incidence of hospital-acquired infections for surgical patients.
The main objective of this randomized clinical trial was to determine the effect of L-arginine supplementation as an adjuvant treatment in patients with essential hypertension. Patients on enalapril and hydrochlorothiazide, with no control of their blood pressure, were randomized to receive either L-arginine (6 g per day) or placebo for six weeks. The results showed an improvement of endothelium-dependent vasodilation, an augmentation of nitric oxide substrate, and an increase in the release of nitric oxide, which in turn resulted in clinical improvement of hypertension.
Some evidence suggests that L-arginine supplementation may enhance exercise performance by increasing the production of nitric oxide in the body, thereby increasing blood flow and oxygen delivery to the muscles. This double-blinded, randomized and placebo-controlled clinical trial aimed to investigate the effect of L-arginine supplementation on sports performance and body composition in male soccer players. Participants were randomized to receive either a placebo or L-arginine (2 g per day) for 45 days. During the trial, sports performance, body mass index (BMI), body fat mass (BFM), and lean body mass (LBM) were measured. In addition, 3-day dietary records were collected at three different time points during the study.
The results showed an improvement in sports performance, as observed by VO2 max results, in the arginine supplemented group; although no significant effect was observed on weight, BMI, BFM, and LBM.
This double-blind, crossover study aimed to determine the effect of L-arginine supplementation on nitric oxide production and efficiency of exercise and exercise tolerance in healthy adults. Participants were randomized to receive either a placebo beverage or a beverage containing 6 g of L-arginine, before completing a series of “step” moderate- and severe-intensity exercise bouts 1 h after ingestion of the beverage.
The results showed a significant increase in plasma nitrite, a biomarker of nitric oxide availability, in the supplemented group, compared to the placebo group. In addition, supplementation with arginine was associated with a reduction in systolic blood pressure, an improvement in VO2 max, and an extension of time to exhaustion during severe-intensity exercise.
The aim of this study was to determine the effect of L-arginine supplementation on endothelial function of microvessels by increasing the production of nitric oxide. Healthy male volunteers were divided into four groups, based on age and physical activity. The skin laser Doppler flux was measured in the microvessels before and after the ingestion of L-arginine (0.9 g). Additionally, endothelium-dependent and independent vasodilation was measure in healthy subjects divided into four age groups. Results showed an increase in endothelium-dependent vasodilation in young trained participants.
This randomized, controlled, double-blind clinical study aimed to evaluate the effect of L-arginine therapy on improving the clinical symptoms of patients with intermittent claudication, in comparison to endothelium-independent vasodilator prostaglandin E1, and control patients. Patients were randomized to receive either L-arginine (8 g twice daily), prostaglandin E1 [PGE1] (40 mcg twice daily), or no therapeutic intervention for three weeks. Participants were assessed for pain-free symptoms and nitric oxide-mediated flow-induced vasodilation or femoral artery. Urinary nitrate and cyclic guanosine-3′, 5′-monophosphate (GMP) were assessed as indices of endogenous nitric oxide production
The results showed an improvement in pain-free walking distance in the l-arginine and PGE1 supplemented group, compared to the control group. In addition, L-arginine supplementation alone improved endothelium-dependent vasodilation and increased plasma and urinary nitrate and cyclic GMP excretion rates, indicating normalized endogenous nitric oxide production.
Blood Sugar Regulation/Diabetes:
The aim of this randomized, double-blind, parallel-group, placebo-controlled phase III clinical study aimed to assess the effect of long-term L-arginine supplementation in preventing or delaying the onset of type II diabetes mellitus (T2DM) in individuals with impaired glucose tolerance and metabolic syndrome. Participants were randomized to receive either placebo or 6.4 g L-arginine per day for 18 months, with an additional 12 month extended follow up, following supplement termination. Fasting glucose levels and glucose tolerance after oral glucose tolerance test were evaluated throughout the study.
At the end of the study, the results show a reduction in the cumulative incidence of diabetes in the arginine supplemented group, compared to the placebo group. L-arginine supplementation also significantly improved insulin sensitivity and β-cell function.
A follow-up study published six years after the original study aimed to determine whether 18 months of supplementation maintained long-lasting effects on diabetic incidence, insulin secretion, insulin sensitivity, oxidative stress, and endothelial function in participants at high risk of developing T2DM. The researchers followed up with the participants without T2DM diagnosis, up to 9 years following the completion of the study.
The results from this second phase of the study suggest that L-arginine supplementation could delay the development of T2DM for a long period. The authors and researchers believe that this effect is due in part, to the effect of L-arginine on the oxidative stress response.
This study aimed to determine whether L-arginine supplementation could improve endothelial function and oxidative stress markers in adults with uncomplicated type 1 diabetes, as well as in a population of adults after an acute bout of exercise. Ten young adult male subjects with uncomplicated type 1 diabetes and twenty matched controls were recruited for this study and randomized to receive either L-arginine (7 g per day for 7 days) or control. The endpoints of this study included lower limb blood flow (using a venous occlusion plethysmography technique), oxidative stress marker (TBARS, Carbonyls), anti-oxidant parameters (uric acid and TRAP) and total NOx in rest conditions and after a single bout of submaximal exercise. The results suggest that L-arginine could improve vascular function in subjects with diabetes by leading to the recovery of basal blood flow to normal levels in type 1 diabetic subjects.
The aim of this randomized, placebo-controlled clinical study was to evaluate the effects of long-term oral L-arginine supplementation on adipose fat mass and muscle free fat mass distribution, daily glucose levels, insulin sensitivity, endothelial function, oxidative stress and adipokine release in obese type 2 diabetic patients with insulin resistance who were treated with a combined period of hypocaloric diet and exercise training.
Participants participated in a hypocaloric diet plus an exercise training program for 21 days, before randomization to receive either a placebo or 8.3 g L-arginine per day. Following supplementation with L-arginine, there was a significant decrease in fat mass and muscle free fat mass distribution, as well as an improvement in mean daily glucose profiles. Additionally, l-arginine supplementation improved antioxidant and nitric oxide levels. The researchers conclude that L-arginine supplementation, in addition to diet and exercise training program had a significant improved effect on glucose metabolism, insulin sensitivity, endothelial function, oxidative stress, and adipokine release in obese type 2 diabetic patients with insulin resistance.